Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Acceptability: total withdrawals · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) probably leads to lower all Withdrawals: All doses of certolizumab pegol vs placebo compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
RR 0.47 [0.39, 0.56]
13 studies · 5200 participants
Moderate

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Withdrawals due to adverse events · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher withdrawals due to adverse events All doses of certolizumab pegol… compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
Peto OR 1.45 [1.09, 1.94]
12 studies · 5236 participants
High